Identification of an intermediate signature that marks the initial phases of the colorectal adenoma-carcinoma transition

International Journal of Molecular Medicine

Volumn 26, Issue 5, 2010, Pages 631-641

  Tang, Hui ^a   Guo, Qiang ^a   Zhang, Chao ^a   Zhu, Jun ^a   Yang, Hui ^a   Zou, Yun Lian ^a   Yan, Yan ^b   Hong, Dong ^a   Sou, Tao ^a   Yan, Xin Min ^a  

^a FIRST PEOPLE S HOSPITAL OF YUNNAN PROVINCE   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Colorectal adenoma; Colorectal carcinoma; Gene expression profiling; Microarray; Signature

Indexed keywords

ADULT; AGED; ARTICLE; COLON MUCOSA; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; EARLY DIAGNOSIS; ENDOSCOPIC THERAPY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECTUM MUCOSA; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 77957860765     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000508     Document Type: Article

References (50)

1. O'Connell JB, Maggard MA and Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96: 1420-1425, 2004. (Pubitemid 39429665)
2. Boyle P and Ferlay J: Cancer incidence and mortality in Europe, 2004. Ann Oncol 16: 481-488, 2005.
3. Sanjoaquin MA, Choodari-Oskooei B, Dolbear C, et al: Colorectal cancer incidence, mortality and survival in South-east England between 1972 and 2001. Eur J Cancer Prev 16: 10-16, 2007.
4. Li M and Gu J: Changing patterns of colorectal cancer in China over a period of 20 years. World J Gastroenterol 11: 4685-4688, 2005.
5. Leslie A, Carey FA, Pratt NR and Steele RJC: The colorectal adenoma-carcinoma sequence. Br J Surg 89: 845-860, 2002.
6. Jeremy JR: Limitations of the adenoma-carcinoma sequence in colorectum. Clin Cancer Res 10: 5969-5970, 2004.
7. Wada R: Proposal of a New hypothesis on the development of colorectal epithelial neoplasia: nonspecific inflammation-colorectal Paneth cell metaplasia-colorectal epithelial neoplasia. Digestion 79: 9-12, 2009.
8. Snover DC, Jass JR, Fenoglio-Preiser C and Batts KP: Serrated polyps of the large intestine: a morphologic and molecular review of an evolving concept. Am J Clin Pathol 124: 380-391, 2005. (Pubitemid 41232924)
9. Lee S, Bang S, Song K and Lee I: Differential expression in normal-adenoma-carcinoma sequence suggests complex molecular carcinogenesis in colon. Oncol Rep 16: 747-754, 2006.
10. Song SY, Kim YH, Yu MK, Kim JH, Lee JM, Son HJ, Rhee PL, Kim JJ, Paik SW and Rhee JC: Comparison of malignant potential between serrated adenomas and traditional adenomas. J Gastroenterol Hepatol 22: 1786-1790, 2007.
11. Kronborg O and Fenger C: Clinical evidence for the adenomacarcinoma sequence. Eur J Cancer Prev 8 (Suppl 1): 73-86, 1999.
12. Smith D, Ballal M, Hodder R, Selvachandran SN and Cade D: The adenoma carcinoma sequence: an indoctrinated model for tumorigenesis, but is it always a clinical reality? Colorectal Dis 8: 296-301, 2006.
13. Qasim A, Muldoon C and McKiernan S: Colonic adenoma patients have higher incidence of hyperplastic polyps on surveillance colonoscopy. Eur J Gastroenterol Hepatol 21: 877-881, 2009.
14. Franzén LE, Hahn-Strömberg V, Edvardsson H and Bodin L: Characterization of colon carcinoma growth pattern by computerized morphometry: Definition of a complexity index. Int J Mol Med 22: 465-472, 2008.
15. Kwon HC, Kim SH, Roh MS, Kim JS, Lee HS, Choi HJ, Jeong JS, Kim HJ and Hwang TH: Gene expression profiling in lymph node-positive and lymph node-negative colorectal cancer. Dis Colon Rectum 47: 141-152, 2004.
16. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D and Yeatman TJ: Osteopontin identified as colon cancer tumor progression marker. C R Biol 326: 1041-1043, 2003. (Pubitemid 38016459)
17. Bandres E, Catalan V, Sola I, Honorato B, Cubedo E, Cordeu L, Andion E, Escalada A, Zarate R, Salgado E, Zabalegui N, García F and Garcia-Foncillas J: Dysregulation of apoptosis is a major mechanism in the lymph node involvement in colorectal carcinoma. Oncol Rep 12: 287-292, 2004.
18. Bertucci F, Salas S, Eysteries S, Nasser V, Finetti P, Ginestier C, Charafe-Jauffret E, Loriod B, Bachelart L, Montfort J, Victorero G, Viret F, Ollendorff V, Fert V, Giovaninni M, Delpero JR, Nguyen C, Viens P, Monges G, Birnbaum D and Houlgatte R: Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 23: 1377-1391, 2004.
19. Birkenkamp-Demtroder K, Christensen LL, Olesen SH, Frederiksen CM, Laiho P, Aaltonen LA, Laurberg S, Sørensen FB, Hagemann R and ØRntoft TF: Gene expression in colorectal cancer. Cancer Res 62: 4352-4363, 2002.
20. Williams NS, Gaynor RB, Scoggin S, Verma U, Gokaslan T, Simmang C, Fleming J, Tavana D, Frenkel E and Becerra C: Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 9: 931-946, 2003.
21. Li M, Lin YM, Hasegawa S, Shimokawa T, Murata K, Kameyama M, Ishikawa O, Katagiri T, Tsunoda T, Nakamura Y and Furukawa Y: Genes associated with liver metastasis of colon cancer, identified by genome-wide cDNA microarray. Int J Oncol 24: 305-312, 2004.
22. Lin YM, Furukawa Y, Tsunoda T, Yue CT, Yang KC and Nakamura Y: Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene 21: 4120-4128, 2002. (Pubitemid 34712879)
23. Yanagawa R, Furukawa Y, Tsunoda T, Kitahara O, Kameyama M, Murata K, Ishikawa O and Nakamura Y: Genome-wide screening of genes showing altered expression in liver metastases of human colorectal cancers by cDNA microarray. Neoplasia 3: 395-401, 2001.
24. Frederiksen CM, Knudsen S, Laurberg S and Orntoft TF: Classification of Dukes' B and C colorectal cancers using expression arrays. J Cancer Res Clin Oncol 129: 263-271, 2003.
25. Fan J, Peng Z, Zhou C, Qiu G, Tang H, Sun Y, Wang X, Li Q, Le X and Xie K: Gene-expression profiling in Chinese patients with colon cancer by coupling experimental and bioinformatic genomewide gene-expression analyses: identification and validation of IFITM3 as a biomarker of early colon carcinogenesis. Cancer 113: 266-275, 2008.
26. Bianchini M, Levy E, Zucchini C, Pinski V, Macagno C, De Sanctis P, Valvassori L, Carinci P and Mordoh J: Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa. Int J Oncol 29: 83-94, 2006.
27. Kleivi K, Lind GE, Diep CB, Meling GI, Brandal LT, Nesland JM, Myklebost O, Rognum TO, Giercksky KE, Skotheim RI and Lothe RA: Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses. Mol Cancer 6: 2, 2007.
28. Galamb O, Sipos F, Solymosi N, Spisák S, Krenács T, Tóth K, Tulassay Z and Molnár B: Diagnostic mRNA expression patterns of inflamed, benign, and malignant colorectal biopsy specimen and their correlation with peripheral blood results. Cancer Epidemiol Biomarkers Prev 17: 2835-2845, 2008.
29. Sabates-Bellver J, Van der Flier LG, de Palo M, Cattaneo E, Maake C, Rehrauer H, Laczko E, Kurowski MA, Bujnicki JM, Menigatti M, Luz J, Ranalli TV, Gomes V, Pastorelli A, Faggiani R, Anti M, Jiricny J, Clevers H and Marra G: Transcriptome profile of human colorectal adenomas. Mol Cancer Res 5: 1263-1275, 2007.
30. Hao XP, Willis JE, Pretlow TG, Rao JS, MacLennan GT, Talbot IC and Pretlow TP: Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. Cancer Res 60: 18-21, 2000.
31. Nyberg P, Salo T and Kalluri R: Tumor microenvironment and angiogenesis. Front Biosci 13: 6537-6553, 2008.
32. Yang CK, Chen DD, Tian Y and Zhang JH: Chemokine IP-10 produced by colorectal carcinoma. Shijie Huaren Xiaohua Zazhi 11: 1703-1705, 2003.
33. Singh UP, Singh S, Iqbal N, Weaver CT, McGhee JR and Lillard JW Jr: IFN-γ;-inducible chemokines enhance adaptive immunity and colitis. J Interferon Cytokine Res 23: 591-600, 2003. (Pubitemid 37323681)
34. Lazzeri E and Romagnani P: CXCR3-binding chemokines: novel multifunctional therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord 5: 109-118, 2005.
35. Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM, Witz IP and Ben-Baruch A: CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 67: 3396-3405, 2007.
36. Myatt SS and Lam EW: The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 7: 847-859, 2007.
37. Kaneda H, Arao T, Tanaka K, Tamura D, Aomatsu K, Kudo K, Sakai K, De Velasco MA, Matsumoto K, Fujita Y, Yamada Y, Tsurutani J, Okamoto I, Nakagawa K and Nishio K: FOXQ1 Is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth. Cancer Res 70: 2053-2063, 2010.
38. Pilarsky C, Wenzig M, Specht T, Saeger HD and Grützmann R: Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia 6: 744-750, 2004. (Pubitemid 40041492)
39. Van den Boom J, Wolter M, Kuick R, Misek DE, Youkilis AS, Wechsler DS, Sommer C, Reifenberger G and Hanash SM: Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol 163: 1033-1043, 2003.
40. Wang Z, Banerjee S, Kong D, Li Y and Sarkar FH: Downregulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res 67: 8293-8300, 2007.
41. Francis RE, Myatt SS, Krol J, Hartman J, Peck B, McGovern UB, Wang J, Guest SK, Filipovic A, Gojis O, Palmieri C, Peston D, Shousha S, Yu Q, Sicinski P, Coombes RC and Lam EW: FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol 35: 57-68, 2009.
42. Wang IC, Meliton L, Tretiakova M, Costa RH, Kalinichenko VV and Kalin TV: Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors. Oncogene 27: 4137-4149, 2008. (Pubitemid 351969912)
43. Teh MT, Wong ST, Neill GW, Ghali LR, Philpott MP and Quinn AG: FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res 62: 4773-4780, 2002.
44. Yoshida Y, Wang IC, Yoder HM, Davidson NO and Costa RH: The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer. Gastroenterology 132: 1420-1431, 2007.
45. Laoukili J, Stahl M and Medema RH: FoxM1: At the crossroads of ageing and cancer. Biochim Biophys Acta 1775: 92-102, 2007.
46. Woenckhaus M, Klein-Hitpass L, Grepmeier U, Merk J, Pfeifer M, Wild P, Bettstetter M, Wuensch P, Blaszyk H, Hartmann A, Hofstaedter F and Dietmaier W: Smoking and cancer-related gene expression in bronchial epithelium and non-small-cell lung cancers. J Pathol 210: 192-204, 2006. (Pubitemid 44463934)
47. Chong IW, Chang MY, Chang HC, Yu YP, Sheu CC, Tsai JR, Hung JY, Chou SH, Tsai MS, Hwang JJ and Lin SR: Great potential of a panel of multiple hMTH1, SPD, ITGA11 and COL11A1 markers for diagnosis of patients with non-small cell lung cancer. Oncol Rep 16: 981-988, 2006.
48. Chang HJ, Yang MJ, Yang YH, Hou MF, Hsueh EJ and Lin SR: MMP13 is potentially a new tumor marker for breast cancer diagnosis. Oncol Rep 22: 1119-1127, 2009.
49. Helm J, Enkemann SA, Coppola D, Barthel JS, Kelley ST and Yeatman TJ: Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Clin Cancer Res 11: 2478-2485, 2005.
50. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D and Yeatman TJ: Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94: 513-521, 2002.